Whitepaper: SARS-CoV-2 vaccines and biosafety
Posted: 9 December 2020 | Merck | No comments yet
Upholding biosafety standards in coronavirus vaccine development and manufacturing despite the acute worldwide need.
Patient safety comes first. This is particularly important for vaccines, which are also used on healthy individuals. On the basis of the regulatory framework, this article focuses on some of the main challenges in proving that a vaccine is both safe in principle and manufactured in a way that ensures patient safety. It also points to some general obstacles that stand in the way of vaccine development.
Related content from this organisation
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
- First-in-class biologic approved for rare lung disease
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Pharmaceutical suspension market to witness accelerated growth
- Immunotherapy drug achieves trial-first in fifty years
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Regulation & Legislation, Research & Development (R&D)
